BI-690517 is under clinical development by Boehringer Ingelheim International and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BI-690517’s likelihood of approval (LoA) and phase transition for Diabetic Nephropathy took place on 09 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BI-690517 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BI-690517 is under development for the treatment of diabetic nephropathy, diabetic and non-diabetic chronic kidney disease. It is administered orally as a film coated tablet and also through intravenous route.
Boehringer Ingelheim International overview
Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.
Quick View BI-690517 LOA Data
|Highest Development Stage|